$HR

Healthcare Realty Trust: Q2 Earnings Snapshot

Healthcare Realty Trust (HR) reported Q2 funds from operations of $143.7 million, or 41 cents per share, beating a Zacks-surveyed analyst average of 40 cents. The company posted a Q2 loss of $43.5 million, or 13 cents per share, and revenue of $281.8 million. Full-year FFO guidance is $1.62 to $1.66 per share.

Original reporting
Published Jul 31, 2026, 5:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 31, 2026, 6:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$HR
Bullish
medium confidence
Mentioned
$HR
Relevance
7/10
AlphAI data visualization · based on local3news.com
Decision brief

The 30-second read

$HRBullishMed
01

Why it matters

The reported FFO beat and the stated full-year FFO guidance range provide a fresh earnings-and-guidance input for traders assessing near-term earnings power and valuation support.

02

Market read

This is a company-specific earnings snapshot with a modestly positive surprise versus consensus and a defined full-year FFO range.

03

What to watch

The article does not discuss property-level fundamentals, leasing spreads, or balance-sheet/financing costs, which can dominate REIT price action after the initial FFO headline.

Relevance 7/10Novelty 6/10Timing: reported Q2 results and full-year FFO range on 2026-07-31

Background

Healthcare Realty Trust is a medical office REIT; funds from operations (FFO) is a key profitability metric in the REIT sector.

Company-level read

Ticker impact

$HRBullishMedium confidence
Context

Healthcare Realty Trust reported Q2 funds from operations of $143.7 million, or 41 cents per share, beating the 40 cents estimate.

Expected impact

Mildly positive bias for the next session and earnings-follow-through, assuming no offsetting guidance or balance-sheet concerns.

Evidence & confidence

The article provides a concrete EPS-like REIT metric beat versus consensus and a specific full-year FFO range, both of which typically drive immediate re-rating in REITs.

Market effects

Adds incremental datapoint on medical office REIT profitability and demand expectations via FFO performance.

Limited, as the disclosure is company-specific rather than a regional macro shock.

Low, since it is a single-issuer earnings snapshot without cross-border policy or capital-market implications.

Counterpoint

A single-quarter FFO beat may not change the longer-term thesis if occupancy, rent growth, or interest-rate sensitivity is deteriorating off-screen.

Key entities

  • Healthcare Realty Trust Incorporated

    Medical office REIT reporting Q2 FFO and providing full-year FFO guidance.

  • Zacks Investment Research

    Provided the consensus estimate referenced in the article.

Related articles

$HRMedAI 8/10

Healthcare Realty Trust (HR) Q2 2026 Earnings Call Transcript

Healthcare Realty Trust (HR) reported Q2 2026 normalized FFO of $0.41/share and same-store cash NOI growth of 5.1% y/y. It raised normalized FFO guidance to $1.62 to $1.66/share and same-store cash NOI growth guidance to 4.3% to 5.0%. GAAP net loss was $0.13/share after $42.7m impairments. HR also discussed $200m JV acquisitions, $83m asset dispositions, and $75m Q2 repurchases.

$HRHigh

Healthcare Realty Trust Inc (HR): Results of Operations and Financial Condition

Healthcare Realty Trust Inc (HR) filed an SEC Form 8-K — Results of Operations and Financial Condition. News Release HEALTHCARE REALTY REPORTS SECOND QUARTER 2026 RESULTS AND FURTHER INCREASES FULL YEAR 2026 GUIDANCE NASHVILLE, Tennessee, July 30, 2026. Healthcare Realty Trust Incorporated (NYSE:HR) today announced results for the second quarter ended June 30, 2026. I n addition, t

$UNFIMedAI 8/10

United Natural Foods (UNFI) Calls the Bottom and Guides for Growth Again

United Natural Foods (UNFI) reported Q4 adjusted EPS of $0.69, beating estimates, but revenue of $7.64B missed expectations. The company guided fiscal 2027 sales to $31.2B-$31.8B, up from $31.15B in 2026. Adjusted EBITDA rose 27% to $701M, and free cash flow hit a record $323M. Management expects fiscal 2027 adjusted EPS of $3.00-$3.50. Hedge fund interest declined in Q2.